Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation

[1]  D. Huntsman,et al.  Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  A. Horwitz,et al.  BRCA1 represses amphiregulin gene expression. , 2010, Cancer research.

[3]  Karthik Devarajan,et al.  Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of BRCA1 or BRCA2 Mutations , 2010, Cancer Prevention Research.

[4]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[5]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[6]  Andrew H. Beck,et al.  MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary , 2009, PloS one.

[7]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[8]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[9]  D. Cleveland,et al.  Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis , 2009, Nature Reviews Molecular Cell Biology.

[10]  V. Abeler,et al.  Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas—an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications , 2009, Virchows Archiv.

[11]  Ashok R Venkitaraman,et al.  Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. , 2009, Annual review of pathology.

[12]  D. Huntsman,et al.  Critical molecular abnormalities in high-grade serous carcinoma of the ovary , 2008, Expert Reviews in Molecular Medicine.

[13]  B. Rosen,et al.  Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma , 2008, Clinical Cancer Research.

[14]  P. Spellman,et al.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.

[15]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[16]  V. Abeler,et al.  Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas , 2006, Modern Pathology.

[17]  R. L. Baldwin,et al.  BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. , 2006, Gynecologic oncology.

[18]  A. Ashworth,et al.  Targeting the DNA repair defect of BRCA tumours. , 2005, Current opinion in pharmacology.

[19]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[20]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[21]  Tina Hernandez-Boussard,et al.  Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles , 2004, Oncogene.

[22]  Yudi Pawitan,et al.  Improved Grading of Breast Adenocarcinomas Based on Genomic Instability , 2004, Cancer Research.

[23]  R. Shiekhattar,et al.  Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. , 2003, Molecular cell.

[24]  P. Duesberg,et al.  Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. , 2003, Cancer genetics and cytogenetics.

[25]  H. Ozçelik,et al.  Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. , 2002, Cancer research.

[26]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[27]  D. Levine,et al.  Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. , 2002, Gynecologic oncology.

[28]  D. Botstein,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[29]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[31]  M. Jasin,et al.  BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.

[32]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[33]  N. Loman,et al.  BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features. , 2000, International Journal of Gynecological Cancer.

[34]  B. Koller,et al.  BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a Brca1 transgene , 1999, Oncogene.

[35]  B. Koller,et al.  Brca1 controls homology-directed DNA repair. , 1999, Molecular cell.

[36]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[37]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Ponder,et al.  Involvement of Brca2 in DNA repair. , 1998, Molecular cell.

[39]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.